Searched for
DR LAL SHARES
JioBlackRock Flexi Cap Fund exits Adani Enterprises, Adani Ports and 3 other companies; adds Tata Motors and 14 more stocksJioBlackRock Flexi Cap Fund exited Adani Enterprises, Adani Ports and three other stocks in May while adding Tata Motors and 14 new stocks ...- Ahead of Market: 10 things that will decide stock market action on WednesdayIndian equities extended gains for a third straight session, with Sensex and Nifty rising on optimism over the Iran-US peace framework and ...
- Sunil Singhania-backed Abakkus Small Cap Fund adds 3 new stocks, increases stake in HDFC Bank, SBI and 49 othersSunil Singhania's Abakkus Small Cap Fund added three new stocks in May, including Tanla Platforms and Intellect Design Arena. The fund also...
- Smallcaps & midcaps rally! Firstsource Solutions, Nuvama, Godfrey Phillips, other stocks jump up to 16%Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...
- Buy, Sell or Hold: Citi upgrades Dr Lal PathLabs; JM Financial initiates coverage on Balkrishna IndustriesBrokerages like Morgan Stanley, Citi, and JM Financial remain selectively positive on Indian equities, spotting opportunities in sectors li...
- Dr. Lal PathLabs shares turn ex-bonus tomorrow for 1:1 issue, last day to buy for eligibilityAs per the corporate filings, the company will issue one fully paid-up bonus equity share of face value Rs 10 for every one existing fully ...
- Add Dr Lal Pathlabs, target price Rs 2,910: HDFC SecuritiesHDFC Securities has an 'add' call on Dr Lal Pathlabs with a target price of Rs 2910. The company reported a total income of Rs 621.80 crore...
- JM Financial upgrades Dr Lal Pathlabs to Buy, target price Rs 3,600JM Financial recommends buying Dr. Lal Pathlabs with a target price of Rs 3,600, citing a potential 25% upside. The company's Q3 earnings s...
- Dr Lal PathLabs Q2 Results: Net profit rises 53%YoY to Rs 111 croreDr Lal PathLabs reported a Rs 72 crore net profit during the corresponding period of the previous year. Revenues rose 12.6% to Rs 601 crore...
- Stock Radar: Breakout from inverse Head and Shoulder pattern may help this healthcare stock hit 52-week highTraders with medium-term investment horizons can look at buying the stock for a possible target of Rs 2,800 in 3-6 months, suggested expert...
- Stock Radar: This healthcare stock eyes fresh 52-week highs after range breakout. Is it a buy?If the breakout from July swing-high sustains, experts see the stock surpassing Rs 2700 levels in 3-4 weeks. High-risk traders can look to ...
- Reduce Dr. Lal Pathlabs, target price Rs 1875: Yes SecuritiesReduce Dr. Lal Pathlabs at a price target of Rs 1875.
- Dr Lal PathLabs Q3 Results: Net profit drops 8% to Rs 54 croreDr Lal PathLabs said its emphasis is on improving the market penetration through franchisee model, and leveraging the digital infrastructur...
- Dr Lal Path Labs cracks 9% on weak Q2 showThe company’s revenue from operations, however, grew 7.1% to Rs 533.8 crore during the period under review, from Rs 498.4 crore in the corr...
- Add Dr. Lal Pathlabs, target price Rs 2,900: Yes SecuritiesDr Lal faces a tough FY23 as Covid ebbs away from revenues even as base quarters had a significant proportion of Covid sales.
- Dr Lal Pathlabs Q4 Results: Profit dips 27% to Rs 62 crRevenue from operations however rose to Rs 485 crore in the fourth quarter as against Rs 431 crore in the year-ago period, Dr Lal Pathlabs ...
- Dr Lal Pathlabs skids 3% as Q3 net profit drops 39% YoYThe company’s EBITDA (earnings before interest, tax, depreciation and amortization) dipped 21.3 per cent to Rs 109 crore in Q3 FY22 over Rs...
- Dr Lal PathLabs Q2 results: Net profit up 11% at Rs 96 croreOperating revenue of the company increased by 15.4 per cent in Q2 FY22 to Rs 498.4 crore as compared with Rs 431.9 crore in Q2 FY21, Dr Lal...
- Market Movers: What spurred rally in NCC, Dr Lal PathlabsDespite a weakness in the headline indices, as many as 40 stocks on the National Stock Exchange gave buy signal based on MACD indicators.
- Buy Dr. Lal Pathlabs, target Rs 1,320: CLSABuy Dr. Lal Pathlabs Ltd. at a price target of Rs 1320.
Load More
